Familial Primary Pulmonary Hypertension: all 352 studies

Page 1 of 4. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary HypertensionRecruitingNCT07604805Not applicable
• Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled TrialEnrolling by invitationNCT07558460Not applicable
• Sotatercept in Pulmonary Arterial HypertensionRecruitingNCT07140484Phase 4
• Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionNot yet recruitingNCT06987097Not applicable
• PAH Exercise StudyRecruitingNCT06941441Phase 3
• imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNceRecruitingNCT06850792Not applicable
• EVE TRIAL , ALMA SYSTAMRecruitingNCT06646653Phase 3
• FreeFlow Percutaneous Atrial Septal Shunt for IPAHRecruitingNCT06605794Not applicable
• Myocardial Work Evaluation in Patients With PAHRecruitingNCT06567379
• Exercise Capacity Muscle Oxygenation and Arterial Stiffness in Children With Pulmonary Arterial HypertensionRecruitingNCT06454838
• Implementing the Wuqinxi on Patients With Pulmonary Arterial HypertensionNot yet recruitingNCT06454422Not applicable
• A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) PatientsEnrolling by invitationNCT06445673
• Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAHRecruitingNCT06350032Phase 3
• Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsRecruitingNCT06317805Phase 4
• The Effects of the Otago Exercise ProgramNot yet recruitingNCT06172790Not applicable
• 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)RecruitingNCT06104228Phase 2
• Endothelial Cell Activation and Total Pulmonary Resistance in PAHNot yet recruitingNCT06035861Not applicable
• Assessing the Utility of Submaximal CPET in Treatment Management of PAHNot yet recruitingNCT05977933
• Anti-CD20 Antibodies for Treatment of SLE-PAHRecruitingNCT05828147Phase 4
• REgistry of Pulmonary Arterial Hypertension Associated With CONNECTIVE Tissue Diseases (RECONNECTIVE)RecruitingNCT05665556
• Telerehabilitation Program Via Videoconference PAH - Randomized Clinical TrialNot yet recruitingNCT05655481Not applicable
• Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible IndividualsRecruitingNCT05584722
• Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)RecruitingNCT05462574
• COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNginaRecruitingNCT05413109Not applicable
• Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial HypertensionRecruitingNCT04972656Not applicable
• Pulmonary Hypertension Biorepository and RegistryRecruitingNCT04808596
• TROPHY PAH Pivotal Study - TReatment of Pulmonary HYpertension for PAH Pivotal StudyNot yet recruitingNCT04570228Not applicable
• Right Ventricular Pacing in Pulmonary Arterial HypertensionRecruitingNCT04194632Not applicable
• Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAHRecruitingNCT04062565Phase 3
• Multi-marker Approach for Risk Assessment in PAHRecruitingNCT03954405
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionEnrolling by invitationNCT03683186Phase 3
• Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)RecruitingNCT03138863Not applicable
• : Vascular Function in Health and DiseaseRecruitingNCT02966665Phase 1
• Hormonal, Metabolic, and Signaling Interactions in PAHRecruitingNCT01884051
• Respiratory and Physical Therapy in Patients With Associated Pulmonary Arterial Hypertension (APAH) With Congenital Heart DefectsRecruitingNCT01397110Not applicable
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)TerminatedNCT05557942Phase 3Results posted
• Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial HypertensionCompletedNCT05439460Phase 4Results posted
• Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAHTerminatedNCT05339087Phase 2Results posted
• Carnitine Consumption and Augmentation in Pulmonary Arterial HypertensionCompletedNCT04908397Phase 1Results posted
• A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)TerminatedNCT04791514Phase 2Results posted
• A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)CompletedNCT04732221Phase 2/3Results posted
• A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)CompletedNCT04712669Phase 2Results posted
• A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance ImagingTerminatedNCT04435782Phase 4Results posted
• Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)CompletedNCT04316143Phase 2Results posted
• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using TyvasoCompletedNCT03950739Phase 1Results posted
• Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAHCompletedNCT03888365Results posted
• A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)CompletedNCT03744637Phase 1Results posted
• A Study of Sotatercept for the Treatment of Pulmonary Arterial HypertensionCompletedNCT03738150Phase 2Results posted
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial HypertensionTerminatedNCT03657095Phase 3Results posted
• Fluoxetine in Pulmonary Arterial Hypertension (PAH) TrialCompletedNCT03638908Phase 2Results posted
• Interventions Against Insulin Resistance in Pulmonary Arterial HypertensionCompletedNCT03617458Phase 2Results posted
• Tamoxifen Therapy to Treat Pulmonary Arterial HypertensionCompletedNCT03528902Phase 2Results posted
• EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial HypertensionCompletedNCT03497689Phase 4Results posted
• A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT03496207Phase 2Results posted
• Investigation of the Safety and Pharmacology of Dry Powder Inhalation of TreprostinilCompletedNCT03399604Phase 3Results posted
• Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive GuidewiresTerminatedNCT03152773Not applicableResults posted
• Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.CompletedNCT03078907Phase 4Results posted
• A Mobile Health Intervention in Pulmonary Arterial HypertensionCompletedNCT03069716Not applicableResults posted
• TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)CompletedNCT03055221Phase 4Results posted
• Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH PatientsTerminatedNCT02939599Phase 2Results posted
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH PatientsTerminatedNCT02927366Phase 2Results posted
• Estrogen Receptor Antagonist in Patients With Pulmonary Arterial HypertensionCompletedNCT02911844Phase 2Results posted
• Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapyCompletedNCT02891850Phase 4Results posted
• Crossover Study From Macitentan or Bosentan Over to AmbrisentanTerminatedNCT02885012Phase 4Results posted
• Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)CompletedNCT02847260Phase 4Results posted
• Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)TerminatedNCT02736149Phase 2Results posted
• Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAHCompletedNCT02734953Phase 2Results posted
• A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)CompletedNCT02664558Phase 2Results posted
• Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYSTTerminatedNCT02657356Phase 3Results posted
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionCompletedNCT02558231Phase 3Results posted
• Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT02551653Phase 1Results posted
• Beta-blockers in Pulmonary Arterial HypertensionTerminatedNCT02507011Phase 2Results posted
• Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAHCompletedNCT02484807Results posted
• Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial HypertensionCompletedNCT02471183Phase 3Results posted
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtensionCompletedNCT02310672Phase 4Results posted
• Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionCompletedNCT02279745Phase 2Results posted
• Safety and Efficacy of APD811 in Pulmonary Arterial HypertensionCompletedNCT02279160Phase 2Results posted
• The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension StudyTerminatedNCT02253394Phase 4Results posted
• Selonsertib in Adults With Pulmonary Arterial HypertensionCompletedNCT02234141Phase 2Results posted
• A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and SpainTerminatedNCT02081690Phase 3Results posted
• Effects of Oral Sildenafil on Mortality in Adults With PAHTerminatedNCT02060487Phase 4Results posted
• Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)TerminatedNCT01934647Phase 1Results posted
• Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)CompletedNCT01926509Phase 1Results posted
• Beraprost-314d Added-on to Tyvaso® (BEAT)CompletedNCT01908699Phase 3Results posted
• Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT InstrumentTerminatedNCT01847014Phase 3Results posted
• Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT InstrumentCompletedNCT01841762Phase 3Results posted
• FK506 (Tacrolimus) in Pulmonary Arterial HypertensionCompletedNCT01647945Phase 2Results posted
• Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial HypertensionCompletedNCT01642407Phase 4Results posted
• Remodulin® to Oral Treprostinil TransitionCompletedNCT01588405Phase 2Results posted
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionCompletedNCT01560637Phase 3Results posted
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral MonotherapyCompletedNCT01560624Phase 3Results posted
• Assessmet of Patients With PAH Right Ventricular VolumeCompletedNCT01557582Not applicableResults posted
• Anastrozole in Patients With Pulmonary Arterial HypertensionCompletedNCT01545336Phase 2Results posted
• A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial HypertensionCompletedNCT01484431Phase 1/2Results posted
• Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®CompletedNCT01477333Phase 2Results posted
• Epoprostenol for Injection in Patients With Pulmonary Arterial HypertensionCompletedNCT01470144Phase 3Results posted
• IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) PatientsCompletedNCT01447628Phase 2Results posted
• Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT01445873Results posted
• Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial HypertensionCompletedNCT01431716Phase 3Results posted
• Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)TerminatedNCT01392495Phase 3Results posted

← Familial Primary Pulmonary Hypertension overview